Company ProfilePremium

McPherson's Limited

Company Profile Analysis

Ticker: MCP.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
McPherson's Limited - Company showcase

Year Founded & Workforce

1860

22 Employees

McPherson's Limited logo

McPherson's Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

McPherson's Limited Overview

McPherson's Limited is a small-cap Australian brand owner in health and beauty. It traces its history to 1860 and is one of the oldest continuously operating companies on the ASX. After more than a decade of selling non-core businesses (printing, housewares, home appliances and, in 2024, Multix), it now focuses on five core brands. Manicare (beauty tools) and Swisspers (cotton) lead their categories in Australia, and Lady Jayne leads hair accessories. Dr. LeWinn's (anti-ageing skincare) and Fusion Health (herbal vitamins and supplements) are challenger brands in larger, faster-growing categories. Manufacturing is fully outsourced, mainly to Asia and Australia. Since FY25 the company has distributed through pharmacy wholesalers and a third-party logistics provider instead of delivering direct to stores. FY26 revenue was $118.3M and underlying EBITDA $4.3M. The company holds net cash, but faces a pending ASIC penalty and needs to show that its brands can grow under the new operating model.


What the company does

McPherson's markets and distributes beauty care, hair care, skin care, vitamins, supplements and personal-care items such as facial wipes, cotton pads and foot-comfort products. It operates in Australia, New Zealand and Asia (FY26 Directors' Report, Principal Activities). It does not manufacture. Production is outsourced to contract manufacturers mainly in Asia and Australia. It keeps a Hong Kong presence for sourcing and quality assurance, and a presence in the People's Republic of China for distribution and sales.

The company's own description (FY26 Annual Report, paraphrased): McPherson's describes itself as a leading supplier of health and beauty products. Most of its revenue comes from five core owned brands that lead their markets (Manicare, Dr. LeWinn's, Swisspers, Lady Jayne and Fusion Health), supported by portfolio brands including Maseur, Revitanail and Bondi fragrances. In the "Likely developments" section of the FY26 Directors' Report, it calls itself a "pure-play health and beauty company" focused on growing its brands.

Strategy framework (FY26 Investor Presentation, slide 9):

Purpose: "Making Confidence Simple."

Vision: to be Australia's leader in premium health and beauty products in every household, every day.

Where it plays: - Leadership positions in established categories: beauty tools, hair accessories, cotton and foot care.

  • Challenger positions in larger, faster-growing categories: beauty transformation, facial skincare and vitamins, minerals and supplements (VMS).

Business and revenue model

DimensionCharacterisation (FY26)
Product / service / subscription / licensing mixAbout 100% branded physical products. There is no subscription or licensing revenue. A small, now-shrinking agency and distribution activity remains: an exclusive distribution agreement for Chemist Warehouse-owned brands outside the Chemist Warehouse network (from July 2022), and historically third-party agency brands that were mostly exited in FY24.
Owned vs portfolioCore brands were 93.4% of FY26 revenue, up from 89.7% in FY25 (FY26 Presentation, slide 15).
Value chain positionAsset-light brand owner and marketer covering brand management, product development, sourcing and quality assurance, sales and A&P. Manufacturing, warehousing (third-party logistics provider from FY25) and much of pharmacy delivery (wholesalers) are outsourced.
Customer typesMajor pharmacy chains, including Chemist Warehouse, the largest customer and a strategic-alliance partner since 2022; independent pharmacies, now served mainly through wholesalers (Symbion, API and at least one other large wholesaler); grocery (supermarket majors); specialty beauty; health food stores (important for Fusion Health); e-commerce marketplaces (Amazon); its own direct-to-consumer sites (Dr. LeWinn's and Fusion Health, launched in FY26); and international distributors, mainly China for Dr. LeWinn's.
End marketsAustralian and New Zealand consumer health and beauty: beauty accessories, cotton, hair accessories, foot care, facial skincare and VMS. International sales were $2.6M in FY26, about 2.2% of revenue.
Key non-IFRS metricCAAP (contribution after advertising and promotion) = gross margin less distribution costs and A&P. FY26 CAAP was $41.6M, a 35.2% margin.

Independent characterisation

McPherson's is a sub-scale owner of consumer brands whose earnings depend heavily on a few Australian pharmacy and grocery buyers. Its three category leaders (Manicare, Swisspers and Lady Jayne) are, in effect, private-label-adjacent accessory brands. They have high shelf share but low pricing power, and they face competition from retailer house brands. The two growth brands, Dr. LeWinn's and Fusion Health, hold small shares (2.3% and 0.6% of their pharmacy categories) in large categories where multinationals dominate.

Divestments and the move to wholesalers have made the business simpler, but they also removed scale. Fixed costs fell faster than revenue only partly, and FY26 underlying EBITDA margin was 3.6%. The balance sheet is clean (net cash, undrawn facilities), and the shares trade below net tangible assets. The investment case now rests almost entirely on whether the company can restore revenue growth in FY27 on a lower fixed-cost base.

Strategy

Stated strategy themes (FY26 AR and Presentation, paraphrased)

  1. Operate as a simplified, streamlined organisation focused on long-term brand growth. This is the main "Likely developments" theme in the FY26 Directors' Report.

  2. "Concentrating investment behind fewer, bigger opportunities" (FY26 presentation, slide 9): five core brands, and the portfolio brands deliberately starved of A&P (portfolio revenue fell 45.9%).

  3. How it competes:

    • Strong brands with creator-led marketing.

    • Disciplined innovation with "bigger, better launches".

    • Retail partnerships that grow customers' categories.

    • Its own direct-to-consumer channels and consumer relationships.

  4. Where it reaches consumers:

    • ANZ retail (pharmacy, grocery, specialty beauty).

    • Digital and international (direct-to-consumer, online retailers, international partners).

Strategic initiatives, last 24 months

InitiativeDatesTargets / status
Route-to-market transformation (3PL plus pharmacy wholesalers)Announced 24 Feb 2025; wholesalers signed Mar–Aug 2025; first full year FY26Target: $4.0–5.0M incremental annual EBIT from FY26, raised to the "upper end" in Jul 2025. Achieved: about $5.6M EBIT and about $2.8M EBITDA. Implementation material items: $9–11M expected in FY25. Pharmacy reach expanded to 4,521 independent pharmacies (IQVIA) from 3,562.
Five-core-brand focus; exit of private label and agenciesAnnounced 15 Nov 2023; completed FY24Core brands now 93.4% of revenue
Multix divestmentJun 2024$19.0M proceeds
Direct-to-consumer e-commerceFY26Dr. LeWinn's and Fusion Health sites launched; "encouraging" or "positive" growth
Amazon marketplace brand storesFY26Several brand stores rolled out
Social and creator-led marketing modelFY26 build, FY27 deploymentCalled a "foundation for FY27 growth"
Salesforce CRM and sales softwareFY24–FY26Capitalised software is the main source of the rise in IT amortisation
ERP programFY26$0.3M expensed as a material item
Branded point-of-sale display stands in major pharmacyFY26Capitalised
Packaging refreshesFY26–FY27Dr. LeWinn's completed; Manicare rolling out in FY27
International distributor-led modelDecided FY26; implementation from FY27Aims to stop International's EBITDA losses (-$1.1M in FY26)
Debt refinancingFY26$15M facility, undrawn
On-market buybackAnnounced 25 Feb 2026 (up to $2M)4,995,130 shares bought for $0.8M by 30 Jun 2026
Board renewal and committee restructureFY26Three committees from 1 Feb 2026; NED minimum shareholding requirement
Sustainability: AASB S2 climate reporting readinessOngoingCovered under governance (FY26 risk section)

FY27 priorities and guidance (27 Aug 2026)

Priorities:

  • Joint business-development planning with customers.

  • Increasing wholesaler SKU availability of the bestseller list.

  • Creator-led consumer marketing.

  • More frequent launches backed by sustained A&P.

  • Greater investment in owned and marketplace e-commerce.

Guidance: Qualitative only. The company is "focused on delivering underlying EBITDA growth for the full year", while noting that weak 4Q26 sales continued into July 2026. No revenue guidance or medium-term financial targets have been published.

Products & Services

Pricing models are not disclosed for any brand. All products are sold wholesale to retailers at list price less trade terms and rebates; since FY25, independent pharmacy is served through wholesalers.

Core brands (all ANZ segment unless noted)

Manicare (beauty tools and accessories)

Description: Australia's leading beauty-accessories brand, covering tweezers, nail clippers and files, manicure and pedicure tools, makeup brushes and sponges, eyelash curlers and facial tools.

Market position: 36.3% value share of total beauty accessories (Circana, Australian grocery and pharmacy, MAT to 28 Jun 2026), category leader.

Target customer: Mass-market female consumers shopping in pharmacy and grocery.

FY26 launches: 12 products, including a Stainless Steel Gua Sha, Metal Face Roller and Silky Hair Bonnet. A packaging refresh began, rolling out in FY27.

Size: FY26 revenue $45.1M, the largest brand at about 38% of group revenue.

Channels: Pharmacy (chains and independents), grocery (grew in FY26 on price initiatives), and a major pharmacy customer (grew).

Watch: Increased competitive dynamics in parts of pharmacy. $2.3M brand impairment in FY26.

Swisspers (cotton and personal care)

Description: Cotton pads, cotton tips and buds, cotton balls, facial wipes and related cotton-care items.

Market position: 67.1% value share of cotton (Circana, 52 weeks to 28 Jun 2026), dominant category leader. MCP brand scan growth was 6.9% against category growth of 5.4%, gaining share.

FY26 launches: Cotton Variety Tips and a Baby Essentials Pack, extending into family care.

Size: FY26 revenue $21.8M (+1.0% reported, +4.1% like-for-like), the only core brand to grow.

Watch: Exposure to cotton commodity and freight costs. Part of a $1.3M combined impairment with Revitanail and Dr. LeWinn's.

Lady Jayne (hair accessories)

Description: Hairbrushes, combs, clips, pins, elastics, styling tools and bonnets.

Market position: 26.9% value share of total hair accessories (Circana, 52 weeks to 28 Jun 2026), category leader.

FY26 launches: Six styling products, including the Infinity Vent Brush, Chrome Shine Brush, Curl Definer Brush, Gem Top Brush, Large Acetate Detangling Comb and French Hair Pin. The brand was repositioned around effortless everyday style with the "Undone to Done" campaign.

Size: FY26 revenue $15.8M (-18.7% reported).

Watch: Ranging losses during the wholesaler transition, reduced promotions, and a delayed electrical range (hair tools).

Dr. LeWinn's (anti-ageing skincare; ANZ and International)

Description: Science-led, clinically inspired anti-ageing skincare with Australian origins. Formerly marketed under the "Dr. LeWinn's Private Formula" heritage; acquired with Revitanail around 2013–2014 (2014 AGM presentation). Includes neck, décolletage and facial treatments.

Named products: Plump + Lift Neck Cream; Smooth + Firm Neck & Décolletage Mask.

Market position: 2.3% of the $814M Australian pharmacy facial-skincare category (Circana, 52 weeks to 28 Jun 2026). Category grew 7.8% but the brand fell 17.8% in scan data.

FY26 developments: Completed a packaging refresh with benefit-led product architecture. Launched a direct-to-consumer e-commerce platform with encouraging growth.

Size: FY26 revenue $15.7M (-22.3%), hurt by out-of-stocks from the packaging refresh and supplier consolidation; resolved in 2H26.

International: China via distributor; weak demand and heavy competitor discounting.

History: Dr. LeWinn's China forecasts are central to the 2020 ASIC matter.

Fusion Health (herbal VMS)

Description: Herbal and nutritional supplements combining traditional Chinese medicine principles with modern herbal formulation. Established in 1999 and acquired with Oriental Botanicals from Blackmores in November 2020 for $27M.

Named products: Magnesium Sleep, Calm Mind and Calm Clear Focus (mental-wellbeing range launched FY26); Women's and Men's Multivitamins (relaunched at more competitive prices); historically an Immunity & Stress capsule.

Market position: 0.6% of the $2.0B Australian pharmacy VMS category. About 38% of brand sales go through the health-food channel, which scan data does not capture.

FY26 developments: Launched a direct-to-consumer e-commerce platform.

Size: FY26 revenue $12.1M (-22.1%).

Watch: Weak innovation performance and impairments of $1.9M in 1H26 and $2.1M for the full year.

Portfolio brands

BrandCategory / descriptionStatus (FY26)
MaseurFoot comfort (massage sandals, insoles)Listed among "iconic household brands" in FY26 releases. Impaired in FY24.
GlamBeauty accessories / beauty transformationListed among iconic brands in the FY26 release. Detail not disclosed.
RevitanailNail treatments and strengthenersPortfolio brand. Impaired in FY24 and FY26.
Bondi fragrancesFragrancePortfolio brand per the FY26 AR. Detail not disclosed.
Oriental BotanicalsHerbal VMS (practitioner origins; pharmacy since 2012)Focus shifted to Fusion in FY24. Impaired in FY24.
MooseheadMen's groomingListed in 2012–2017 materials. Current status not confirmed in FY26 sources.
A'kin / Al'chemyNatural skincare and haircare (acquired Dec 2014)Listed in FY23 materials. Absent from FY26 brand lists. Current status not publicly disclosed in the sources reviewed.
Chemist Warehouse brands (distributed under the exclusive distribution agreement)Includes Wagner Vitamins, Wagner Body Science, Bondi Protein, Foster Grant, INC, Microgenics, distributed outside the CWG networkAgreement runs from 1 Jul 2022 for an initial five years. Revenue below expectations. The related inventory prepayment was fully impaired in FY24 ($3.7M impairment plus $1.2M amortisation).

Exited or divested lines (last 5 years)

Multix: (bags, wraps, foils): sold June 2024.

Private label: exited FY24.

Agency brands: Sugarbaby (JV) and Eylure exited during FY24. Revenue from private label and non-strategic agency brands was $8.8M in FY23 and $4.7M in FY24.

Kotia: deer-milk skincare JV: status not disclosed in recent filings.

Historical agencies: P&G fine fragrances (Gucci, Dolce & Gabbana, Hugo Boss) from 2014, Trilogy (2014) and Karen Murrell. All are absent from recent filings.

Financial Narrative

Income statement

Sources: FY26 Remuneration Report five-year table (continuing NPAT, underlying NPAT, underlying EBITDA, EPS, dividends); FY23, FY24, FY25 and FY26 results releases; FY26 Presentation slides 15 and 27.

Table notes:

  • FY22 figures include Multix, which was continuing at the time.

  • FY25 total-group underlying EBITDA of $9.5M includes $2.2M from the discontinued Multix tail.

  • FY23 continuing statutory NPAT (-$1.3M) is from the FY26 five-year table. The FY24 release gives the FY23 group loss per share as 3.5 cents, the same figure the five-year table attributes to continuing operations; this is a disclosure inconsistency.

  • Group FY25 loss per share was 10.5 cents.

FY24 group basic loss per share was 11.1 cents: - Operating income (EBIT) is not presented on a statutory basis by the company. Statutory operating loss before finance costs was -$19.0M in FY25 and -$25.5M in FY26.

Revenue CAGR (continuing, FY23→FY26): -8.7% a year (calculated).

Revenue CAGR (total group basis, FY22→FY24): -3.9% a year (calculated).

Commentary. The revenue trend falls into three phases:

FY22–FY24 (portfolio pruning): Total revenue fell from $214.0M to $197.6M as private label and agencies were exited and Multix lost share to grocery private label.

FY24–FY25 (Multix removed, core brands steady): Continuing revenue fell 3.9%, of which $4.1M came from exiting non-strategic brands. Core brands grew 1.9%, helped by about $5M of transitional pipe-fill.

FY26 (transition shock): Revenue fell 14.9% (10.1% like-for-like). Of the $20.7M decline:

  • $7.1M came from accounting and route-to-market effects: wholesaler rebates now netted against revenue and the reversal of FY25 pipe-fill.

  • $7.4M came from underlying core-brand weakness.

  • $6.2M came from portfolio brands.

Gross margin rose 0.9 points to 58.8% because the mix shifted toward core brands, partly offset by rebate dilution. CAAP margin fell 2.8 points to 35.2% because 3PL distribution costs rose by $2.2M.

The key point is operating leverage. The new model removed $6.8M of employee costs and $1.4M of other costs, but CAAP fell by $11.2M, so underlying EBITDA fell $3.0M. Underlying NPAT has been roughly break-even for three years. The repeated statutory losses ($11.4M, $16.6M and $20.3M) come from impairments and restructuring, which total about $58M of pre-tax material items in continuing operations over FY23–FY26.

FY26 vs FY25 underlying cost structure

Structural benefits of the new model in FY26 (FY26 Presentation, slide 19):

  • Revenue/gross-margin line: -$3.2M.

    • Warehouse and logistics rebates: -$3.2M.

    • Distribution: +$1.7M from reduced delivery costs.

    • New 3PL services: -$3.4M.

  • Fixed costs (exit of warehouse staff and overheads): +$7.7M.

  • Net EBITDA benefit: about +$2.8M.

  • Depreciation and amortisation saved (Kingsgrove exit): +$2.8M.

  • Net EBIT benefit: about +$5.6M, slightly above the original $4–5M EBIT target.

Material items

Table notes: - FY24 impairments include $3.7M on the Chemist Warehouse distribution prepayment (plus $1.2M of amortisation) and $2.8M on other non-core brands.

  • The FY25 component split is only partly disclosed. Impairment was $10.2M per the income statement; the rest covered redundancy, onerous lease ($3.2M) and other items, offset by a $1.3M foreign currency translation reserve gain.

  • FY26 impairments were $15.0M of goodwill (ANZ) and $5.7M of brands (Manicare $2.3M, Fusion $2.1M, and $1.3M across Swisspers, Revitanail and Dr. LeWinn's).

  • FY26 total also includes the $2.3M ASIC costs, a $0.8M onerous lease, and $0.3M of ERP costs, less a $0.1M ATO interest benefit.

  • The $2.0M ASIC penalty provision recognised after balance date is included within FY26 provisions and other items.

Balance sheet

Sources: FY26 consolidated balance sheet; FY24 results release (net cash $14.1M; FY23 net debt $6.5M); FY26 statement of changes in equity (FY24 closing equity $89.6M); FY25 cash flow statement (FY24 closing cash $24.8M).

Table notes:

Net cash excludes lease liabilities: - Discrepancy: FY26 balance-sheet cash ($5.110M) less borrowings ($0.345M) is $4.8M, but the company reports net cash of $4.5M. The sources do not reconcile the $0.3M gap; the company figure is shown.

  • NTA per share: the 4E table header order suggests FY25 19c and FY26 20c, consistent with calculated tangible equity (about $26.8M FY25 and $27.3M FY26).

  • FY26 accumulated losses were $167.4M against contributed equity of $216.4M. This retained-loss balance is the stated reason no dividends can be paid.

Debt facility: Refinanced during FY26 to a $15M facility "right-sized" for the new model. It was undrawn throughout FY26 and the company states it complied with covenants (FY26 AR Note 1(a) and Note 18). Covenant terms and maturity are not disclosed in the sources reviewed.

Commentary. The balance sheet is simpler and contains less goodwill after FY26. Intangibles fell from $46.2M to $24.5M, so the risk of further write-downs is now lower in dollar terms. Inventory rose 32% to $26.2M to fix the Dr. LeWinn's out-of-stocks and buffer uneven wholesaler orders, which consumed most of the year's cash. The going-concern assessment explicitly considered the ASIC penalty, but the auditor did not raise a material uncertainty.

Cash flow

Sources: FY26 and FY25 cash flow statements; FY24 results release. FY23 operating cash flow is from the FY24 release. Underlying cash conversion was 51% in FY23 and 129% in FY22 (FY23 release).

FY26 operating cash flow includes a $2.0M ATO refund announced on 19 Feb 2026. Without it, operating cash flow would have been about -$1.3M. FY24 dividends were 2.0c per share paid on 22 Mar 2024; the cash amount is not in the sources reviewed.

Commentary.

  • Cash generation has weakened sharply: operating cash flow fell from $12.3M in FY24 (helped by inventory release) to $0.7M in FY26.

  • After lease payments, the business consumed about $3.5M of cash in FY26.

  • The 1H26 position ($12.6M net cash at 31 Dec 2025) turned into $4.5M by June 2026. This came from the inventory rebuild, payment in July 2025 of restructuring costs, the buyback, and weak 2H trading.

Risk: If FY27 earnings do not recover, the combination of the ASIC penalty (provision $2.0M; the actual penalty could be "materially higher or lower") and leftover Kingsgrove lease costs could push the company into net debt.

Ratios

Ratios are calculated from the financial statements: - ROIC uses a 30% tax rate and invested capital = equity + borrowings + leases − cash.

  • Negative net-debt-to-EBITDA means net cash.

  • Working-capital day counts are distorted: receivables include GST and are gross of rebates and claims, and payables include A&P, rebate and customer-claim accruals. Trend the figures; do not compare them with peers.

  • A cash conversion cycle cannot be computed reliably; the indicative figure is about 45–50 days, a blunt approximation.

Commentary.

  • Returns are negative on a statutory basis and close to zero on an underlying basis.

  • Liquidity is adequate (current ratio about 1.5×) and financial gearing is negligible.

  • Operational gearing is the problem: a fixed-cost base of about $37M (employee plus other costs) sits on about $42M of CAAP. Every 1% of revenue lost costs about $0.35M of EBITDA at the FY26 CAAP margin.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentWhat it containsProducts / brands

Australia and New Zealand (ANZ)

All domestic sales into pharmacy (chains and, through wholesalers, independents), grocery, specialty beauty, health food, Australian and NZ e-commerce and direct-to-consumer. Goodwill is allocated to the ANZ cash-generating unit.

Manicare, Swisspers, Lady Jayne, Dr. LeWinn's, Fusion Health, Maseur, Glam, Revitanail, Bondi fragrances, and Chemist Warehouse brands under the exclusive distribution agreement

International

Export and offshore sales, mainly Dr. LeWinn's in China. Historically included Singapore agency and distributor sales, exited in FY24. A move to a distributor-led model is to start in FY27.

Dr. LeWinn's (main), Manicare (small)

Corporate (unallocated)

Group costs. Segment EBITDA excludes corporate costs.

—

Revenue by Segment

SegmentFY2023FY2024FY2025FY2026

ANZ revenue (AUD Mn)

146.6139.1135.9115.8

International revenue (AUD Mn)

9.35.63.02.6

Group revenue continuing (AUD Mn)

155.2144.6139.0118.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

SegmentFY2023FY2024FY2025FY2026

ANZ underlying EBITDA (AUD Mn)

17.612.812.99.6

International underlying EBITDA (AUD Mn)

-1.3-0.6-1.6-1.1

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2024FY2025FY2026

ANZ EBITDA margin (%)

9.29.58.3

International EBITDA margin (%)

-10.7-53.3-42.3

ANZ revenue YoY growth (%)

-5.1-2.3-14.8

International revenue YoY growth (%)

-40.5-46.4-16.3

ANZ share of group revenue (%)

96.197.897.9

International share of group revenue (%)

3.92.22.2

Revenue by Segment (FY2025–FY2026)

Brand (AUD Mn)FY2025FY2026

Manicare

47.945.1

Swisspers

21.621.8

Lady Jayne

19.415.8

Dr. LeWinn's

20.215.7

Fusion Health

15.612.1

Total core brands

124.6110.5

Revenue by Segment (%)

Brand performance (%)FY26 reported growth (%)FY26 like-for-like growth excl. rebates and pipe-fill (%)

Manicare

-5.7-0.1

Swisspers

1.04.1

Lady Jayne

-18.7-14.4

Dr. LeWinn's

-22.3-15.5

Fusion Health

-22.1-16.9

Core brands total

-11.3-6.1

Portfolio brands total

-45.9-44.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment and Revenue by Segment (%)

MetricFY2024FY2025FY2026

Core brand revenue (AUD Mn)

122.4124.6110.5

Core brand share of revenue (%)

84.689.793.4

Revenue by Segment (1H2025–1H2026)

Brand (AUD Mn)1H20251H2026

Manicare

23.925.5

Swisspers

10.511.8

Lady Jayne

9.69.4

Dr. LeWinn's

10.98.6

Fusion Health

7.66.7

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue total group incl Multix (AUD Mn)

214.0210.3197.6——

Revenue continuing ops (AUD Mn)

—155.2144.6139.0118.3

Gross profit continuing (AUD Mn)

———80.569.6

Gross margin continuing (%)

———57.958.8

A&P expense continuing (AUD Mn)

———22.320.5

CAAP continuing underlying (AUD Mn)

———52.841.6

Underlying EBITDA total group (AUD Mn)

17.515.015.29.54.3

Underlying EBITDA continuing (AUD Mn)

17.512.17.77.34.3

Underlying EBITDA margin continuing (%)

8.27.85.35.23.6

Underlying EBIT continuing (AUD Mn)

———0.70.2

Material items pre-tax continuing (AUD Mn)

—3.712.719.725.6

Statutory pre-tax profit continuing (AUD Mn)

———-19.7-25.7

Underlying NPAT continuing (AUD Mn)

7.02.3-0.4-0.1-0.5

Statutory NPAT continuing (AUD Mn)

0.3-1.3-11.4-16.6-20.3

Statutory NPAT total group (AUD Mn)

0.3-5.1-16.0-15.0-20.3

Statutory net margin continuing (%)

0.2-0.8-7.9-11.9-17.1

Basic EPS continuing (AUD cents)

0.3-3.5-7.9-11.5-14.2

Underlying EPS continuing (AUD cents)

5.31.6-0.30.0-0.3

Diluted EPS continuing (AUD cents)

———-11.5-14.2

Dividends per share (AUD cents)

5.03.02.000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Business Lines

LineFY2025FY2026

Revenue (AUD Mn)

139.0118.3

Gross margin (AUD Mn)

80.569.6

Distribution costs (AUD Mn)

5.37.5

A&P (AUD Mn)

22.320.5

CAAP (AUD Mn)

52.841.6

Employee costs (AUD Mn)

31.724.9

Other expenses (AUD Mn)

13.812.4

Underlying EBITDA (AUD Mn)

7.34.3

Depreciation and amortisation (AUD Mn)

6.54.1

Underlying EBIT (AUD Mn)

0.70.2

Components

ComponentFY2024FY2025FY2026

Intangible impairments (AUD Mn)

6.510.220.7

Restructuring and transformation (AUD Mn)

1.7—1.5

ASIC legal and regulatory costs (AUD Mn)

——2.3

Total material items continuing (AUD Mn)

12.719.725.6

Balance Sheet and Per-Share Data

MetricFY2023FY2024FY2025FY2026

Total assets (AUD Mn)

——117.296.9

Cash and equivalents (AUD Mn)

—24.89.55.1

Inventories (AUD Mn)

——19.826.2

Trade and other receivables current (AUD Mn)

——29.530.5

Intangible assets incl goodwill (AUD Mn)

——46.224.5

Borrowings current (AUD Mn)

——0.70.3

Borrowings non-current (AUD Mn)

——00

Lease liabilities total (AUD Mn)

——6.65.8

Net cash company definition (AUD Mn)

-6.514.18.84.5

Total equity (AUD Mn)

—89.673.051.8

Working capital current assets less current liabilities (AUD Mn)

——22.921.3

Trade working capital receivables plus inventory less payables (AUD Mn)

——20.724.8

NTA per share (AUD cents)

——1920

Cash Flow

MetricFY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

6.512.32.20.7

Capex PP&E plus intangibles (AUD Mn)

—2.73.61.3

Free cash flow OCF less capex (AUD Mn)

—9.6-1.4-0.6

Lease principal repayments (AUD Mn)

——3.72.9

Free cash flow after leases (AUD Mn)

——-5.1-3.5

Dividends paid (AUD Mn)

——00

Share buybacks (AUD Mn)

0000.8

Net borrowing repayment (AUD Mn)

——10.20.1

Divestment proceeds (AUD Mn)

019.000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025FY2026

ROE statutory on average equity (%)

-18.5-32.5

ROA statutory on average assets (%)

—-18.9

ROIC underlying after-tax EBIT on invested capital approx (%)

0.70.3

Current ratio (x)

1.611.51

Debt to equity borrowings only (%)

0.90.7

Debt to equity incl leases (%)

10.011.9

Net debt to underlying EBITDA (x)

-1.2-1.0

Interest coverage underlying EBIT over borrowing costs (x)

0.70.4

Asset turnover (x)

—1.10

Days sales outstanding approx (days)

7794

Days inventory on materials cost approx (days)

123196

Days payables on materials cost approx (days)

178240

Revenue by Region

RegionFY2023FY2024FY2025FY2026

Australia and New Zealand (AUD Mn)

146.6139.1135.9115.8

International mainly China (AUD Mn)

9.35.63.02.6

Growth (%)

Growth (%)FY2024FY2025FY2026

ANZ YoY growth (%)

-5.1-2.3-14.8

International YoY growth (%)

-40.5-46.4-16.3

Share Price and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Share price at fiscal year end (AUD)

0.660.400.410.250.14

Dividends per share (AUD cents)

5.03.02.000

Performance Details

Performance (price only, fiscal-year-end basis)Value

1-year (Jun 2025 → Jun 2026)

-44%

3-year (Jun 2023 → Jun 2026)

-65%

4-year (Jun 2022 → Jun 2026)

-79%

5-year

Not available (FY21 year-end price not in sources reviewed)

Since FY26 year end (Jun 2026 → about 1 Sep 2026)

About -11%

Valuation Snapshot

MultipleValueBasis

Market capitalisation

About A$17.4M

Derived

Enterprise value excluding leases

About A$12.9M

Market cap less $4.5M net cash

EV including leases

About A$18.7M

Plus $5.8M lease liabilities

EV / underlying EBITDA FY26

About 3.0× (excluding leases)

$4.3M EBITDA, which is pre-AASB 16 adjusted only in part

EV / Sales FY26

About 0.11×

$118.3M revenue

Price / Book

About 0.34×

$51.8M equity

Price / NTA

About 0.63×

20c NTA per share

Peer multiples

Not compiled

No comparable ASX peer set

Analyst Conclusions

Management guidance

FY27: Qualitative only. The company is "focused on delivering underlying EBITDA growth" from the FY26 base of $4.3M. It acknowledges that weak sales continued into July 2026. No revenue guidance.

Long-term incentive hurdles (not guidance): FY28 underlying EPS of 2.27–3.67c, implying underlying NPAT of about $3.2–5.1M.

Consensus expectations

Not available (no broker consensus identified).

Bull case

  1. Costs fixed; recovery depends on revenue. The new model has permanently removed about $7.7M of fixed costs and $2.8M of depreciation. If like-for-like core-brand revenue simply returns to FY25 levels (about $124M, versus $110.5M in FY26) at a CAAP margin of about 35%, underlying EBITDA could plausibly double from $4.3M. Much of the FY26 hit came from one-off transition effects ($7.1M of rebate and pipe-fill impacts) and from out-of-stocks that are now fixed.

  2. Leadership brands are intact. Manicare, Swisspers and Lady Jayne all kept their category-leading shares, and Swisspers gained share. Distribution has widened by about 950 pharmacies. When wholesaler SKU optimisation fixes ranging, this wider reach could turn into volume, as already seen with the largest wholesaler (sales and volumes up in FY26).

  3. Asset backing and optionality. EV is about $13M, against $4.3M of EBITDA, net cash and NTA of 20c against a share price of about 12.5c. The brands are market leaders. That creates downside support and possible corporate interest, for example from Chemist Warehouse, which is already a strategic shareholder and alliance partner.

Bear case

  1. Structural share loss, not just transition. Brands declined in four of five growing categories. Fusion and Dr. LeWinn's are falling 15–17% like-for-like, and portfolio brands fell 44%. Management has missed its own guidance three times in six months (February, April and July 2026).

  2. Overhangs cluster in 2027. The ASIC penalty hearing (April 2027) and the end of the Chemist Warehouse alliance's initial term (June 2027) both fall in the same window. Either could hit cash, ranging or sentiment, at a time when net cash is only $4.5M and free cash flow after leases is negative (about -$3.5M in FY26).

  3. Sub-scale economics. At about $118M of revenue, a fixed base of about $37M (employee plus other costs) and $20M of A&P leave little room for error. More impairments are possible on the remaining $24.5M of intangibles if FY27 forecasts are missed, and retained losses rule out dividends for the foreseeable future.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Oct–Nov 20262026 AGM: trading update for 1Q–early 2Q FY27; remuneration report vote (strike risk after nil STI and a statutory loss); any chair succession signals
OngoingWholesaler SKU ranging gains; Circana share trends for Manicare, Lady Jayne and Dr. LeWinn's
Feb 20271H27 results: like-for-like core-brand growth, CAAP margin recovery, net cash, buyback status
6 Apr 2027ASIC penalty hearing (or an earlier appeal decision)
By 30 Jun 2027Chemist Warehouse strategic alliance renewal or renegotiation; expiry of the Kingsgrove lease (22 Jun 2027), which removes a residual cost
FY27Execution of the international distributor model; direct-to-consumer and Amazon scale; launch frequency and success, especially Fusion's mental-wellbeing range and Lady Jayne's electrical range
Any timeCorporate activity (none disclosed); substantial-holder changes

Analyst verdict

McPherson's has completed the restructuring that its last three CEOs worked toward. It has exited printing, housewares, appliances, Multix, private label, agencies and its own warehouse, leaving a pure-play portfolio of health and beauty brands with an asset-light cost base and no debt. The problem is that this restructuring has not produced profitable growth.

FY26 was intended to be the first year in which the new route to market paid off. Instead, revenue fell 14.9% and underlying EBITDA fell 41%, and a further $20.7M of intangibles was written off. The structural savings of $5.6M at EBIT level were delivered as promised, but trading losses more than absorbed them. The execution misses were Dr. LeWinn's out-of-stocks, delayed launches, weak innovation at Fusion and ranging losses in independent pharmacy. Management's guidance was revised three times in six months.

At about A$0.125 per share the market is pricing the company as being in steady decline. The enterprise value of about $13M is about 3× FY26 EBITDA, and the shares trade at roughly 0.6× NTA. That price does not credit category-leading positions of 36–67% in beauty tools and cotton, or a fixed-cost base that has finally been reset. If like-for-like core-brand revenue can be stabilised in 1H27, the operating leverage is meaningful. If it cannot, the 2027 cluster of risks (ASIC penalty, Chemist Warehouse renewal, a thin cash buffer and possibly further impairments) leaves little margin for error.

Our assessment is speculative and execution-dependent, with a negative near-term skew. The thesis can be tested quickly: 1H27 results in February 2027 must show positive like-for-like growth in core brands, a recovery in CAAP margin and stable net cash. Absent that, the most plausible way for shareholders to realise value is corporate activity rather than organic recovery. The low valuation and fragmented share register make that possible, but nothing has been disclosed. Investors should size any position for binary outcomes and watch the AGM trading update, the Circana share data and the Chemist Warehouse renewal closely.


End of dossier. All figures are in AUD and from company filings unless otherwise noted. Items marked "not disclosed" or left blank in chartable tables were not found in the primary sources reviewed and have not been estimated. Derived figures (market capitalisation, shares on issue after the buyback, ratios, valuation multiples) are calculations from the cited filings and are labelled as such.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleAppointedPrior rolesEducation

Brett Charlton

CEO & Managing Director

1 Aug 2023

More than 30 years in consumer goods across Asia Pacific with Diageo, PepsiCo, Fonterra, Sanofi and private equity; later advisory and consulting

BCom (Marketing and HR), Griffith University; IMD Lausanne graduate; FAICD

Mark Sherwin

Chief Financial Officer

6 May 2024

Not detailed in the sources reviewed

—

Craig Durham

General Counsel & Company Secretary (not KMP)

15 Jan 2024

35-year career in legal and governance roles in beverages, intelligent traffic systems, gaming technology and financial services

LLB (Hons) QUT; LLM Melbourne; Grad Dip Legal Practice; Grad Dip Applied Corporate Governance; FGIA; GAICD; admitted in Qld, Vic and New York

“—” = not publicly disclosed.

Directors' Remuneration

ComponentB. Charlton FY2025B. Charlton FY2026M. Sherwin FY2025M. Sherwin FY2026

Salary and fees

618,900631,146448,068458,755

Annual leave accrual

9,44919,0437,65610,152

Cash bonus (one-off discretionary)

093,780044,800

Superannuation

30,00030,00029,93230,000

Long service leave

3,0358,4991,8384,968

Share-based payments

-139,89770,8252,49514,388

Total remuneration

521,487853,293489,989563,063

Board of Directors

DirectorRoleIndependentAppointedCommitteesBackgroundShares held

Ari Mervis

Chair (21 Jul 2021–10 Mar 2025; again from 1 Feb 2026)

Yes

16 Feb 2021

Chair, Nominations

Former Chair and Executive Chair of Endeavour Group; Executive Chair of Accolade Wines; CEO & MD of Murray Goulburn; SABMiller (CEO CUB, MD Asia Pacific). BCom, University of the Witwatersrand. Former Myer director (2021–2024).

150,000

Brett Charlton

CEO & MD

No

1 Aug 2023

—

See above

100,000

Alison Cook

NED; interim Chair 10 Mar 2025–31 Jan 2026

Yes

24 Jul 2018

Chair, Remuneration, People & Culture; member, Audit & Risk and Nominations

Former COO and CEO of Genetic Technologies (ASX/NASDAQ); 30+ years in biopharma. BSc, MSc (Microbiology); GAICD

35,500

Helen Thornton

NED

Yes

20 Dec 2021

Chair, Audit & Risk; member, Remuneration, People & Culture and Nominations

Chartered Accountant; former VP Risk Management at BlueScope; BHP, Deloitte, KPMG. NED of Arena REIT, Ansvar Insurance and Beyond Bank. BEc, Monash

20,000

John Batistich

NED

Yes

17 Nov 2025

Member, Audit & Risk, Remuneration, People & Culture, and Nominations

Marketing and digital executive at Westfield, PepsiCo, Kimberly-Clark, Wrigley and Lion Nathan. NED of Adairs and Foodco; former NED of Zip Co (2018–2024). BBus, MMgt; GAICD

80,000

Jane McKellar

NED (retired 31 Jan 2026)

Yes

Not stated in sources

Former Chair, People & Culture

—

11533 (at retirement)

Board & Management Changes

DateChange

10 Dec 2020

Laurence McAllister departs as CEO & MD; Grant Peck becomes interim CEO

31 Mar 2021

Peck becomes permanent CEO & MD

21 Jul 2021

Mervis succeeds Graham Cubbin as Chair

2023

Peck departs; he later became non-executive chair of Mighty Craft. Exact exit date not in sources reviewed.

1 Aug 2023

Brett Charlton becomes CEO & MD

15 Jan 2024

Craig Durham becomes General Counsel & Company Secretary

30 Apr 2024

CFO Paul Witheridge retires

6 May 2024

Mark Sherwin becomes CFO

10 Mar 2025

Mervis steps down as Chair; Cook becomes interim Chair

17 Nov 2025

Batistich joins the board

31 Jan / 1 Feb 2026

McKellar retires; Mervis resumes as Chair; committees restructured

Major Shareholders

HolderShares%Source / date

Investors Mutual Limited

12,495,8608.68

InvestSMART substantial-holder register (date of notice not shown)

Pinnacle Investment Management Group

10,726,0147.45

InvestSMART substantial-holder register (date of notice not shown)

Chemist Warehouse Group (now within Sigma Healthcare after their 2025 merger)

about 14.2M issued 1 Jul 2022

9.9 at issue

MCP release, 1 Jul 2022. Current holding not confirmed in the sources reviewed.

Directors (combined, current board)

385,500

about 0.3

FY26 Remuneration Report

Competitive Landscape

Competitors by Segment

Category (MCP brand)CompetitorOwner / typeNotes

Beauty tools (Manicare)

Retailer house brands (Chemist Warehouse, Priceline, Coles, Woolworths)

Private label

Main threat in a commoditised category

Beauty tools (Manicare)

Tweezerman

Zwilling group

Premium tools

Beauty tools (Manicare)

Revlon beauty tools

Revlon

Mass tools

Cotton (Swisspers)

Supermarket and pharmacy private-label cotton

Private label

Swisspers holds 67.1% of the measured category

Hair accessories (Lady Jayne)

Goody

Newell Brands

Global hair accessories

Hair accessories (Lady Jayne)

Kitsch; scünci

Independent / Conair

Trend-led accessories

Hair accessories (Lady Jayne)

Retailer house brands

Private label

—

Facial skincare (Dr. LeWinn's)

L'Oréal (L'Oréal Paris, Garnier, CeraVe, La Roche-Posay)

L'Oréal

Dominant in pharmacy skincare

Facial skincare (Dr. LeWinn's)

Olay

Procter & Gamble

Anti-ageing

Facial skincare (Dr. LeWinn's)

Neutrogena

—

Mass derm

Facial skincare (Dr. LeWinn's)

Nivea

Beiersdorf

Mass skincare

Facial skincare (Dr. LeWinn's)

The Ordinary

Estée Lauder (DECIEM)

Value "science-led" positioning, a direct overlap

Facial skincare (Dr. LeWinn's)

Natio; Sukin

Australian brands

Local challengers

VMS (Fusion Health)

Blackmores

Kirin Holdings (acquired 2023)

Seller of Fusion; three-year non-compete expired in 2023

VMS (Fusion Health)

Swisse

H&H Group

Market leader

VMS (Fusion Health)

Nature's Way; Herbs of Gold; Ethical Nutrients; Cenovis

Various

Herbal and practitioner overlap

VMS (Fusion Health)

Wagner and other Chemist Warehouse house brands

Chemist Warehouse

MCP distributes some of these outside CWG, a co-opetition relationship

Peer Comparison FY2026

CompanyFiscal yearRevenueRevenue growthMargin indicatorR&D intensity

McPherson's

FY26 (Jun)

AUD 118.3M

-14.9%

Underlying EBITDA margin 3.6%; gross margin 58.8%

—

Beiersdorf

CY2024

About EUR 9.9B

—

Not compiled in this research

Not compiled

Haleon

CY2024

About GBP 11.2B

—

Not compiled in this research

Not compiled

Kenvue

CY2024

About USD 15.5B

—

Not compiled in this research

Not compiled

“—” = not publicly disclosed.

Recent Developments

--

Company Snapshot

$76.3M

Revenue

22

Employees

1860

Founded

where the lease expires on June, Australia

Headquarters

SWOT Analysis

Strengths

  • Category leadership: Manicare holds 36.3% of beauty accessories, Swisspers 67.1% of cotton and Lady Jayne 26.9% of hair accessories (Circana, FY26).
  • Net-cash balance sheet: Net cash of $4.5M and an undrawn $15M facility at 30 June 2026 (FY26 AR).
  • Lower fixed-cost base: Employee costs fell from $31.7M to $24.9M (-21.5%), with about $5.6M of structural EBIT benefit from the new model (FY26 Presentation).
  • Gross-margin resilience: Gross margin rose to 58.8% (+0.9 points) despite wholesaler rebates, helped by a core-brand mix of 93.4% (FY26 Presentation).
  • Wider distribution: Reach in independent pharmacy rose to 4,521 outlets from 3,562, about 950 more (IQVIA, FY26 Presentation).
  • Strategic alliance with the largest pharmacy retailer: Chemist Warehouse is an aligned shareholder (9.9% at issue) under preferred-brand and exclusive-distribution agreements running to June 2027 (2022 releases).
  • Shares below tangible value: About 12.5c share price against NTA of 20c per share (FY26 4E), which limits downside in a liquidation-value framework.

Weaknesses

  • Revenue shrinking: Continuing revenue fell from $155.2M (FY23) to $118.3M (FY26), a compound decline of 8.7% a year.
  • Thin profitability: Underlying EBITDA margin was 3.6%, underlying EBIT $0.2M and underlying NPAT -$0.5M in FY26.
  • Repeated impairments: Impairments of $8.3M (FY23 Multix), $18.3M (FY24 group), $10.2M (FY25) and $20.7M (FY26) show past capital allocation that destroyed value.
  • Execution failures: Dr. LeWinn's out-of-stocks (revenue -22.3%), a delayed Lady Jayne electrical range, and Fusion innovation performing "below expectations" (FY26 AR).
  • Weak cash conversion: FY26 operating cash flow of $0.7M included a $2.0M tax refund; free cash flow after leases was about -$3.5M.
  • Sub-scale A&P and small shares in growth categories: A&P of $20.5M across all brands; 2.3% of facial skincare and 0.6% of pharmacy VMS.
  • Repeated guidance misses: Guidance moved from "moderate EBITDA growth" in February 2026 to "no growth" in April and a 41% fall by July 2026.

Opportunities

  • Wider pharmacy reach: Converting the new reach (about 950 more outlets) into sales of the bestseller range through wholesaler SKU optimisation (FY27 priority).
  • Direct-to-consumer and Amazon: Scaling the channels launched in FY26, where early trading was described as "positive" and "encouraging".
  • Growing categories: Facial skincare (+7.8%) and VMS (+5.3%) are growing; small share gains would be material relative to MCP's revenue base.
  • International turnaround: Moving to a distributor model could remove up to $1.1M of annual EBITDA losses.
  • Grocery momentum: Grocery grew for Manicare and Swisspers on price and promotional initiatives in FY26.
  • Potential acquisition target: At an implied enterprise value of about $13M, below NTA, and with brands that lead their categories, McPherson's could attract a trade buyer or private equity. This is speculative; no approach has been disclosed.

Threats

  • Chemist Warehouse alliance renewal: The initial five-year term ends 30 June 2027. Non-renewal is flagged as a key risk in the FY26 AR.
  • ASIC penalty: The penalty hearing is scheduled from 6 April 2027. The $2.0M provision "may be materially higher or lower" (FY26 AR).
  • Private-label pressure: This already caused Multix to be sold (FY24 release) and is cited in Manicare's competitive dynamics in FY26.
  • Currency: The AUD/USD rate matters because the US dollar is the main sourcing currency. A weaker AUD hurt FY24 EBITDA (FY24 release).
  • Supplier concentration: Key suppliers are in China and Australia. Supplier consolidation contributed to the Dr. LeWinn's out-of-stocks (FY26 AR).
  • China weakness: International revenue fell from $9.3M to $2.6M over FY23–FY26.
  • Further impairment risk: $24.5M of intangibles remain on the balance sheet. ANZ goodwill and brand value depend on forecast growth (PwC key audit matter).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
24 Feb 2025 (context)Transformation update: exit warehousing and direct-to-store delivery in favour of 3PL plus wholesalers; $4–5M EBIT targetSets up the FY26 transition
26 Feb 2025 (context)1H25 results: revenue $70.7M (-7.6%), underlying EBITDA $2.0M, net cash $11.6M; about 65 warehouse roles affectedBaseline before transition
27 Mar 2025Symbion three-year wholesale agreement from 1 Jun 2025 ($10–15M of annual revenue)First wholesaler announced
2 Jun 2025Federal Court liability hearing in ASIC v McPherson's begins (as scheduled)Legal overhang
18 Jul 2025Expected FY25 results: revenue about $139.0M, EBITDA $7.0–7.5M; route-to-market benefit at the upper end of $4–5M EBITPre-announcement
15 Aug 2025API wholesale agreement ($15–20M of annual revenue), the last major wholesalerTransition fully contracted
27 Aug 2025FY25 results: revenue $139.0M (-3.9%), core brands $124.6M (+1.9%), underlying EBITDA $7.3M, statutory loss $15.0M, material items $19.7M, net cash $8.8MAbout $5M of pipe-fill flattered FY25
29 Sep 2025FY25 Annual Report and AGM notice released—
1 Oct 2025CEO and CFO fixed pay increased by about 3%Remuneration
31 Oct 2025AGM (hybrid, Thomson Geer, Sydney). Remuneration report passed with 83.01% in favour. CEO address calls brand rebuilding a "multi-year effort".Governance
3 Nov 2025FY26 LTI grant: Charlton 2,761,000 EPS rights and 1,381,000 TSR rights; Sherwin 1,037,000EPS and TSR hurdles to FY28
17 Nov 2025John Batistich appointed independent NEDAdds marketing and digital skills
1H FY26 (timing not specified)Head office moved from Kingsgrove to 383 Kent St, Sydney; $0.8M onerous lease chargeCost base
31 Jan / 1 Feb 2026Jane McKellar retires; Mervis resumes as Chair; Audit and Risk committees merged; Nominations Committee createdBoard renewal
19 Feb 2026ATO refund announcement ($2.0M, received in FY26)Supported FY26 operating cash flow
25 Feb 20261H26 results: revenue $66.0M (-6.7%), underlying EBITDA $2.2M (+10.6%), core brands $61.9M (+2.2% like-for-like), net cash $12.6M, statutory loss $2.3M, Fusion impairment $1.9M; guidance of "moderate" FY26 EBITDA growthPeak of confidence
25 Feb 2026On-market buyback of up to $2M announcedCapital return
FY26 (ongoing)Dr. LeWinn's and Fusion Health direct-to-consumer sites launched; Amazon brand stores; creator-led marketing capability builtDigital pivot
FY26Debt facilities refinanced to $15M, undrawnLiquidity
23 Apr 2026Trading update: no longer expects EBITDA growth for FY26; cites trading conditions, macro factors and supplier surchargesFirst downgrade
30 Apr 2026NED minimum shareholding requirement takes effect (five-year phase-in)Alignment
May–Jun 2026Buyback executed in daily tranches at about $0.115–0.14—
14 Jul 2026Preliminary FY26: revenue $115–120M, EBITDA $4.0–4.5M (implied 2H26 $1.8–2.3M), impairments $15–20M, net cash $4.5M; buyback total 4,995,130 shares / $0.8M. Shares fell about 9% to $0.145.Second downgrade
13 Aug 2026Trading halt, then Federal Court judgment ([2026] FCA 1130, Markovic J). MCP breached continuous disclosure from 12 to 30 Nov 2020 and engaged in misleading conduct; former MD McAllister breached ss 180(1) and 1309(12). $2.0M provision. Shares fell about 23% to about $0.123.Legal liability established
20 Aug 2026FY26 investor briefing call notice—
27 Aug 2026FY26 results: revenue $118.3M (-14.9%), underlying EBITDA $4.3M (-41.4%), statutory loss $20.3M, impairments $20.7M ($15.0M goodwill), no dividend, international moving to a distributor model, FY27 focus on EBITDA growthReset year
28 Aug 2026Court declarations made; two-day penalty hearing from 6 Apr 2027 (subject to any appeal by MCP)Timing of penalty
1 Sep 2026Notification of cessation of securities (cancellation of bought-back shares); share price about $0.125–0.133—
About 28 Sep 20262026 Annual Report scheduled (InvestSMART calendar); 2026 AGM date not confirmed in sources reviewedUpcoming governance event

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

10 charts
Income Statement: Revenue & Gross Profit (FY2022–FY2026): Revenue total group incl Multix fell from AUD 214 Mn in FY2022 to AUD 197.6 Mn in FY2024.
McPherson's Limited — Income Statement: Revenue & Gross Profit (FY2022–FY2026)
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue total group incl Multix214210.3197.6——
Revenue continuing ops—155.2144.6139118.3
Gross profit continuing———80.569.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.